Innoviva, Inc. (INVA)
About Innoviva, Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $411.3M
- Net income
- $4.4M
- Total assets
- $1.6B
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.6B
- Dividend yield
- 4.84%
- Shares outstanding
- 76.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 5, 2004
Innoviva, Inc. (INVA) Stock Price
- Profitable — net income of $4.4M in FY2025.
- Trading 15% below its 52-week high.
- Pays a dividend yielding about 4.84% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Innoviva, Inc..
Write a review
News about Innoviva, Inc.
News & sentiment via Polygon.io
Innoviva, Inc.: frequently asked questions
Is Innoviva, Inc. an American company?
Innoviva, Inc. is a US-based company headquartered in Burlingame, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Innoviva, Inc. headquartered?
Innoviva, Inc. is headquartered in Burlingame, California, United States.
Is Innoviva, Inc. publicly traded?
Yes — Innoviva, Inc. is a publicly traded company. Its stock trades under the ticker symbol INVA on the NASDAQ.
What does Innoviva, Inc. do?
Innoviva, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
